Evidence map›Paper›PMID 18314107›Full record

ArticleFertility and sterility2009

Defining the proliferative phase endometrial defect.

Jason G Bromer, Tamir S Aldad, Hugh S Taylor

Abstract read
In one paragraph

Article in Fertility and sterility, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. The Impact of Endometriosis on Pregnancy.Journal of personalized medicine · 2024
    Review
  7. Evolutionary divergence of embryo implantation in primates.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2022
    Review
  8. Article
  9. Encapsulated VEGFJournal, genetic engineering & biotechnology · 2021
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jason G BromerDepartment of Obstetrics, Division of Reproductive Endocrinology and Infertility, Yale University School of Medicine, New Haven, Connecticut 06520, USA.
Tamir S Aldad
Hugh S Taylor

Funding

Tissue Factor and EmdometriosisU54HD052668 · NICHD · YALE UNIVERSITY · PI TAYLOR, HUGH SMITH · 2007 to 2011
$6.6M
Hox Gene Expression in Human EndometriumR01HD036887 · NICHD · YALE UNIVERSITY · PI TAYLOR, HUGH S · 2003 to 2007
$1.4M
NICHD NIH HHS R01 HD036887NICHD NIH HHS U54 HD052668
6 · The paper itself

Abstract

objectiveTo evaluate proliferative phase endometrial development in a heterogeneous infertility population.

designRetrospective study.

settingUniversity-based infertility practice. PATIENT(S): Two hundred forty-six treatment cycles. INTERVENTION(S): Clomiphene citrate or FSH ovarian stimulation, followed by IUI or IVF. MAIN OUTCOME MEASURE(S): Endometrial thickness according to transvaginal ultrasonography; clinical pregnancy rate. RESULT(S): Endometrial growth began from a nadir of approximately 4.5 mm on cycle day 4 and increased linearly to a plateau of approximately 10 mm on cycle day 9. This same pattern was observed in all cycles, regardless of pregnancy, drug, or underlying diagnosis. Follicle-stimulating hormone-stimulated cycles showed a significantly increased endometrial thickness compared with clomiphene citrate cycles (10.1 vs. 8.3 mm). Maximum endometrial thickness achieved showed a correlation with age, body mass index, and maximum E(2) level. Subjects who carried a primary diagnosis of polycystic ovary syndrome, endometriosis, or recurrent pregnancy loss all achieved a significantly lower peak endometrial thickness than control subjects. There was a trend toward increased endometrial thickness in cycles resulting in pregnancy compared with those not (10.1 vs. 9.6 mm, respectively). CONCLUSION(S): Endometrial development follows a predictable pattern, with a plateau in growth at cycle day 9. Diseases associated with infertility manifest a proliferative phase defect that can be recognized clinically.

Indexed as

Abortion, HabitualAdultClomipheneEndometriosisEndometriumFemaleFertility Agents, FemaleFertilization in VitroFollicle Stimulating HormoneFollicular PhaseHumansInfertility, FemaleInsemination, ArtificialMiddle AgedOvulation InductionPolycystic Ovary SyndromeClomipheneFertility Agents, FemaleFollicle Stimulating Hormone

Identifiers

PMID18314107
PMCPMC2699408

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.